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Background. Recently, it has been shown that liquid L-T4 formulation can be ingested with breakfast. This study looked to extend
these findings by investigating whether a soft gel capsule formulation of L-T4 could also be ingested at breakfast time. Methods.
60 patients (18–65 yrs), previously submitted to thyroidectomy for proven benign goitre in stable euthyroidism receiving liquid
L-T4 therapy ingested with breakfast, were enrolled. TSH, fT4, and fT3 levels were assessed in all the patients who were switched
from liquid L-T4 to a soft gel capsule formulation at the same dosage of L-T4. After 6 months, TSH, fT4, and fT3 levels were
determined again. Results.There were no differences in TSH levels, but fT3 and fT4 levels during treatment with the soft gel capsule
were significantly lower than those at enrolment with the liquid L-T4 formulation (TSH median (min–max): 1.9 (0.5–4.0) versus
2.2 (0.5–4.5) mIU/L, fT3: 2.5 (2.4–3.1) versus 2.7 (2.4–3.3) pg/mL, 𝑝 < 0.05, and fT4: 9.9 (8.0–13) versus 10.6 (8.6–13.8) pg/mL,
𝑝 < 0.0001). Conclusion. Both liquid and soft gel formulations of L-T4 can be taken with breakfast. However, liquid L-T4 would be
the preferred formulation for patients in whom even small changes in fT4 and fT3 levels are to be avoided.
1. Introduction
Levothyroxine (L-T4) is used worldwide as replacement
therapy for patients with hypothyroidism, and for the last few
years it has been the thirdmost commonly dispensed therapy
in the United States [1]. Synthetic L-T4 as a therapeutic agent
was first used in the 1950s and was widely adopted as the
primary agent for thyroid hormone replacement, replacing
the natural desiccated thyroid extract that had been used over
the previous 50-year period [2].
Although replacement therapy with levothyroxine has
been prescribed for more than 60 years and is generally con-
sidered straightforward, cross-sectional surveys of patients
on treatment with levothyroxine demonstrate that between
40% and 48% are either overtreated or undertreated [3, 4].
There are many potential explanations for this. Firstly, a
number of factors may interfere with intestinal absorption
of L-T4, including food, dietary fibre, coffee, drugs, gastric
or intestinal resection, and disease [5]. As a result, current
guidelines recommend that L-T4 is taken in a fasting state at
least 30 minutes before breakfast [6–8].
Secondly, it is not always reliable to followmedical advice,
especially for drug therapy [9]; this is especially relevant
for L-T4 therapy as a significant number of patients have
problems in postponing their breakfast by 30–60 minutes to
ensure that they take L-T4 in the fasting state [10]. In the
therapeutic scenario the recent introduction of nontablet L-
T4 formulations, such as liquid and soft gel capsules, would
seem to raise doubts as to this recommendation [5].
The results of a recent randomized, double-blind,
placebo-controlled crossover trial showed that a liquid L-T4
formulation can be ingested during each patient’s normal
breakfast, mixed with tea, coffee, milk, cappuccino, orange
juice, and so forth, thus potentially improving therapeutic
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compliance [11]. This study, the “TITI” study (Tirosint-
versus-Tiche study, IBSA Italia), looked to extend these
findings by investigating whether an L-T4 soft gel capsule
formulation could also be safely and effectively administered
to stable euthyroid patients during each patient’s normal
breakfast without any malabsorption.
2. Subjects and Methods
Eligible patients were selected by a search in the database
for those treated and followed up at the Thyroid Unit
of the Department of Clinical and Experimental Sciences,
University of Brescia, Italy. Eligibility (search) criteria were
as follows: (a) treatment of hypothyroidism with liquid L-
T4 (IBSA Farmaceutici Italia Srl., Lodi, Italy) ingested during
each patient’s normal breakfast; (b) stable levothyroxine
replacement over the last 6 months; (c) complete personal
medical history; and (d) details of current drug therapy and
any previous therapy. In order to avoid any possible con-
founders (i.e., the need to increase L-T4 therapy in patients
affected by Hashimoto’s thyroiditis during the study span) we
enrolled only patients who had previously undergone total
thyroidectomy for proven benign goitre.
All participants had tomaintain the same breakfast habits
and any ongoing therapy for the entire period of the study.
All patients were assessed for thyroid-stimulating hor-
mone (TSH), free T4 (fT4), and free T3 (fT3) levels and
were switched from liquid L-T4 to the soft gel capsule
formulation at the same dosage of L-T4, ingested during each
patient’s normal breakfast. Serum concentrations of TSH,
fT4, and fT3 were once again established after six months.
All patients gave their informed consent to participate in
the study, conducted in accordance with the Declaration of
Helsinki. Institutional Review Board approval for this study
was obtained.
Serum concentrations of fT4 (normal range 8.0–
19.0 pg/mL, analytical sensitivity 1 pg/mL), fT3 (normal range
2.4–4.7, analytical sensitivity 0.35 pg/mL), and TSH (normal
range 0.4–4.5mIU/L, analytical sensitivity 0.004mIU/L)
were measured using a fully automated Architect i2000
analyzer (Abbott Diagnostics, Abbott Park, IL, USA) based
on chemiluminescent magnetic immunoassay.
3. Statistical Analysis
Statistical analyses were performed using SPSS 17.0 software
(SPSS, Inc., Evanston, IL, USA). Normal distribution was
checked by the Shapiro-Wilk test. TSH, fT4, and fT3 levels
distribution levels were nonnormally distributed and were
not normalized by the usual procedures of data trans-
formation; in these cases results are presented as median
with minimum andmaximum values. Comparisons between
continuous variables were performed by paired samples 𝑡-
test or related samples by the Wilcoxon signed rank test, as
appropriate.
Two-tailed 𝑝 < 0.05 was considered statistically signifi-
cant.
4. Results
Of the 2371 assessed patients with hypothyroidism, 60 (51
females and 9 males, aged 47.7 ± 11.2 years) were eligible
for the inclusion criteria and were enrolled for the study. All
patients were euthyroid based on test results conducted 6
months before recruitment whilst receiving stable liquid L-
T4 therapy ingested with breakfast (mean dosage 106.25 ±
24.28 𝜇g/day). A detailed description of breakfast composi-
tion, particularly related to insoluble fibres and/or soya milk,
was obtained in each subject (Table 1).
The thyroid hormonal profiles during administration of
liquid L-T4 six months before recruitment, at enrolment and
after 6 months’ treatment with L-T4 soft gel capsules, are
shown in Table 2. There were no differences in TSH levels
at the three different time points, but during treatment with
the soft gel capsule formulation fT3 and fT4 levels were
significantly lower than those found 6months before recruit-
ment and at enrolment with the liquid L-T4 formulation. No
patients developed hypothyroidism during the period of the
study.
A subgroup analysis was conducted on the last 30 con-
secutive patients using data after three months of treatment
with L-T4 soft gel capsules (Table 3). There were no sig-
nificant differences in hormone levels between 6 months
before recruitment, enrolment, and at 3 months. Significant
reductions in fT3 and fT4 levels were observed between 3 and
6months’ treatment with L-T4 soft gel capsules whereas there
was a slight increase in TSH value.
5. Discussion
The main finding of this study is that both the liquid and
soft gel capsule formulations of L-T4 can be taken with
breakfast. Priority should however be given to the liquid L-
T4 formulation in those patients where even a small change
in fT4 and fT3 levels is to be avoided.
Current guidelines for the treatment of hypothyroidism
recommend ingesting levothyroxine in the fasting state 60–
30 minutes before breakfast or at bedtime, at least three
hours after the evening meal, for optimal and consistent
absorption [6–8]. This recommendation is based on study
data demonstrating that concomitant ingestion of food [12–
15], fibre [16], soya products [17], and coffee [13] is associated
with higher serum TSH values in hypothyroid subjects
treated with L-T4 as compared with the fasting state. Taking
L-T4with coffee, or withwater followed by coffeewithin a few
minutes, results in a poor TSH response inmany patients [13].
The recent introduction of new nontablet formulations of L-
T4, such as soft gel capsules and a liquid, could resolve this
problem [5]. In one small study of hypothyroid patients, Vita
et al. observed that the absorption of a soft gel preparation of
L-T4 (Tiche capsules, IBSA, Switzerland)was not impaired by
taking it with coffee [10].The same authors also reported that
the problem of incomplete absorption of L-T4 caused by pro-
ton pump inhibitor-induced increases in gastric pH was not
observed with the L-T4 soft gel formulation [18].Morelli et al.
demonstrated that there is therapeutic equivalence in liquid
L-T4 administration at breakfast or 10min beforehand [19].
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Table 1: Breakfast composition and concomitant drug treatment of the patients in the study.
Patient Gender Age Breakfast Concomitant drug(s) assumed at breakfast
1 F 54 Tea Calcium
2 F 60 Milk —
3 F 44 Tea —
4 M 53 Coffee & yogurt —
5 F 68 Coffee & biscuits & yogurt —
6 M 55 Coffee & yogurt —
7 F 60 Cappuccino PPI
8 F 47 Cappuccino & biscuits —
9 F 43 Coffee & biscuits —
10 F 51 Cappuccino & fibres —
11 M 40 Tea & biscuits —
12 F 46 Coffee & fibres & yogurt —
13 F 35 Coffee & milk & fibres Iron
14 F 51 Cappuccino & orange juice —
15 F 59 Coffee & milk & fibres PPI
16 F 61 Tea & yogurt —
17 M 51 Coffee & soya milk & fibres Calcium
18 F 55 Coffee & yogurt Calcium
19 F 44 Coffee & milk & fibres & biscuits —
20 F 49 Coffee & biscuits Calcium
21 F 27 Cappuccino & biscuits —
22 F 36 Coffee & biscuits —
23 F 55 Milk & biscuits & fibres —
24 F 66 Orange juice PPI
25 F 64 Fibres & fruits —
26 F 69 Milk & biscuits —
27 F 29 Orange juice —
28 F 34 Cappuccino —
29 F 55 Cappuccino & biscuits —
30 F 59 Coffee & biscuits —
31 F 46 Coffee —
32 F 60 Coffee & biscuits Calcium-PPI
33 M 53 Tea & biscuits & yogurt —
34 F 40 Cappuccino & biscuits —
35 F 24 Tea & biscuits —
36 F 48 Coffee & milk & fibres —
37 M 45 Coffee & biscuits —
38 F 47 Coffee & fibres & yogurt PPI
39 F 40 Coffee —
40 F 30 Tea & biscuits —
41 F 42 Milk —
42 F 43 Milk & biscuits —
43 F 36 Milk & biscuits —
44 F 47 Cappuccino & biscuits Calcium
45 F 53 Milk & fibres —
46 F 56 Milk —
47 F 24 Orange juice & biscuits & fibres —
48 F 54 Coffee & biscuits —
49 F 41 Tea & biscuits —
50 F 41 Tea —
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Table 1: Continued.
Patient Gender Age Breakfast Concomitant drug(s) assumed at breakfast
51 F 49 Milk & fibres —
52 F 43 Tea & fibres —
53 F 25 Coffee —
54 F 65 Coffee & biscuits Calcium
55 M 65 Soya milk & biscuits PPI
56 F 53 Cappuccino & biscuits —
57 M 45 Tea —
58 F 43 Coffee & biscuits PPI
59 F 49 Cappuccino & biscuits —
60 M 37 Tea & orange juice —
PPI: proton pump inhibitors.
Table 2: Thyroid hormone levels six months before recruitment and at enrolment (both when taking liquid L-T4) and after 6 months’
treatment with L-T4 soft gel capsules.
6 months before recruitment At enrolment 6 months after soft gel capsule
TSH (mIU/L) 1.9 (0.5–4.1) 1.9 (0.5–4.0) 2.2 (0.5–4.5)
fT4 (pg/mL) 10.5 (8.6–13.8) 10.6 (8.6–13.8) 9.9 (8.0–13)∗
fT3 (pg/mL) 2.7 (2.4–3.6) 2.7 (2.4–3.3) 2.5 (2.4–3.1)+
Median (min–max).
∗
𝑝 < 0.0001 versus 6 months before recruitment and at enrolment; +𝑝 < 0.05 versus 6 months before recruitment and at enrolment.
Table 3: Thyroid hormone levels six months before recruitment and at enrolment (both when taking liquid L-T4) and after 3 and 6 months’
treatment with L-T4 soft gel capsules (𝑛 = 30).
6 months before recruitment At enrolment 3 months after soft gel capsule 6 months after soft gel capsule
TSH (mIU/L) 1.9 (0.5–4.0) 1.9 (0.5–4.0) 2.0 (0.5–4.5) 2.2 (0.7–4.4)
fT4 (pg/mL) 10.5 (8.6–13.7) 10.5 (8.6–13.6) 10.4 (9.1–13) 9.9 (8.8–13.3)∗
fT3 (pg/mL) 2.8 (2.4–3.6) 2.7 (2.4–3.2) 2.7 (2.4–3.1) 2.5 (2.4–3.4)∗
Median (min–max).
∗
𝑝 < 0.05 versus at 3 months after soft gel capsule treatment, at enrolment, and before recruitment.
We have previously observed that taking L-T4 at 30
minutes before having breakfast was not associated with
alterations in optimal TSH, fT4, and fT3 concentrations in
a group of patients taking their dose of a liquid L-T4 formu-
lation (Tirosint, IBSA, Italy) with coffee [20]. More recently,
we clearly demonstrated in a randomized, placebo-controlled
double-blind crossover trial that the thyroid hormone profiles
are almost identical after the administration of the same dose
of oral liquid L-T4 either with breakfast or in the fasting state
(30 minutes before breakfast) [11]. This study confirms and
extends these previous findings. To the best of our knowledge,
no previous study has made comparisons between soft gel
capsule and liquid formulations of L-T4 taken at breakfast
time. The clinical relevance of the significant reduction in
fT4 and fT3 serum levels after switching from liquid to soft
gel capsule L-T4 is not clear. However, no patient developed
hypothyroidism after 6 months of switching formulations.
Nevertheless, further analysis of data on the last 30 patients
would appear to indicate a progressive reduction in fT4 and
fT3 levels after the switchover as time passed.At threemonths
from switching over from liquid to soft gel capsule L-T4, TSH,
fT4, and fT3 levels were superimposable on those found at
recruitment, but reductions were seen over the next 3months
of therapy (i.e., by 6 months). The TSH had again slightly
increased but the change was not of statistical significance.
Based on these findings, it would be reasonable to assume
that absorption of the soft gel capsule L-T4 formulation
gradually diminishes as time passes when ingested with
breakfast.
This study could be limited by the relatively short follow-
up time. A longer follow-up during soft gel capsule treatment
could yield further information on the trend of thyroid hor-
monal profile and the clinical significance of the hormonal
changes demonstrated by this study. For this reason, large
longitudinal prospective studies are needed to clarify this
important issue.
In conclusion, the results of this study suggest that, in
general, both the liquid and soft gel capsule formulations of
L-T4 can be taken with breakfast. Priority should however
be given to the liquid L-T4 formulation in those patients
where even small changes in fT4 and fT3 levels need to
be avoided, such as those receiving suppressive therapy
for thyroid cancer and/or cardiopathic patients receiving
substitutive L-T4 therapy.
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